## Roger E Mclendon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/805135/publications.pdf

Version: 2024-02-01

107 papers 17,948 citations

43 h-index 100 g-index

109 all docs

109 docs citations

109 times ranked 22759 citing authors

#	Article	IF	CITATIONS
1	Central Nervous System Tumor Classification. Hematology/Oncology Clinics of North America, 2022, 36, 1-21.	2.2	1
2	Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. Neuro-Oncology Practice, 2022, 9, 317-327.	1.6	3
3	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro-Oncology, 2022, 24, 1989-2000.	1.2	27
4	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications, 2021, 12, 352.	12.8	77
5	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	1.2	46
6	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
7	Histologic maturation of cerebral neuroblastoma following conventional chemotherapy. Pediatric Blood and Cancer, 2021, 68, e29034.	1.5	1
8	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
9	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
10	A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.0	10
11	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathologica, 2020, 139, 277-286.	7.7	36
12	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical Cancer Research, 2020, 26, 1141-1151.	7.0	43
13	The integrated genomic and epigenomic landscape of brainstem glioma. Nature Communications, 2020, $11,3077.$	12.8	50
14	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
15	Glioneuronal Tumor With Features of Ganglioglioma and Neurocytoma Arising in the Fourth Ventricle: A Report of 2 Unusual Cases and a Review of Infratentorial Gangliogliomas. Journal of Neuropathology and Experimental Neurology, 2019, 78, 780-787.	1.7	8
16	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. Cancer Research, 2019, 79, 3383-3394.	0.9	30
17	Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. Acta Neuropathologica Communications, 2019, 7, 42.	5.2	57
18	ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nature Communications, 2019, 10, 1023.	12.8	87

#	Article	IF	CITATIONS
19	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. Neuro-Oncology, 2019, 21, vi7-vi7.	1.2	5
20	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. Neuro-Oncology Advances, 2019, 1, vdz036.	0.7	4
21	Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Science Advances, 2019, 5, eaav9879.	10.3	17
22	Sudden Unexpected Death in a Child From an Anaplastic Ependymoma. American Journal of Forensic Medicine and Pathology, 2019, 40, 275-278.	0.8	3
23	Intraventricular Pilocytic Astrocytoma With <i>KIAA1549/BRAF</i> Fusion Arising in a 44-Year Old. Journal of Neuropathology and Experimental Neurology, 2019, 78, 187-190.	1.7	6
24	Two Extraordinary Sellar Neuronal Tumors. American Journal of Clinical Pathology, 2019, 151, 241-254.	0.7	5
25	Sensitive and rapid detection of <i>TERT </i> promoter and <i>IDH </i> mutations in diffuse gliomas. Neuro-Oncology, 2019, 21, 440-450.	1.2	27
26	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2019, 78, 57-64.	1.7	8
27	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research, 2018, 24, 3611-3631.	7.0	39
28	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.9	82
29	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Research, 2018, 78, 36-50.	0.9	35
30	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications, 2018, 9, 2087.	12.8	124
31	Recurrent Glioblastoma Treated with Recombinant Poliovirus. New England Journal of Medicine, 2018, 379, 150-161.	27.0	570
32	Intracerebral Flexner-Wintersteiner Rosette-Rich Tumor With Somatic RB1 Mutation: A CNS Embryonal Tumor With Retinoblastic Differentiation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 846-852.	1.7	1
33	Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience, 2018, 56, 163-168.	1.5	31
34	Novel case of recurrent intraventricular atypical central neurocytoma with prominent gangliogliomatous differentiation in a 10â€yearâ€old boy with 10 years of follow up. Neuropathology, 2018, 38, 542-548.	1.2	3
35	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
36	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 696-702.	1.7	38

#	Article	IF	CITATIONS
37	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research, 2017, 15, 507-520.	3.4	41
38	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research, 2017, 23, 1898-1909.	7.0	215
39	Histone H3.3K27M Represses <i>p16</i> to Accelerate Gliomagenesis in a Murine Model of DIPG. Molecular Cancer Research, 2017, 15, 1243-1254.	3.4	120
40	The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. Journal of Neuropathology and Experimental Neurology, 2017, 76, 189-194.	1.7	2
41	Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. Journal of Experimental Medicine, 2017, 214, 245-267.	8.5	123
42	<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. Cancer Research, 2017, 77, 6097-6108.	0.9	46
43	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
44	Epilepsy in neurofibromatosis type 1. Epilepsy and Behavior, 2017, 73, 137-141.	1.7	35
45	Structured Annual Faculty Review Program Accelerates Professional Development and Promotion. Academic Pathology, 2017, 4, 2374289516689471.	1.1	10
46	Morphological and molecular features of astroblastoma, including <i>BRAFV600E</i> mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. Neuro-Oncology, 2017, 19, 31-42.	1,2	45
47	Single-Agent Carboplatin for a Rare Case of Pilomyxoid Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1. Case Reports in Oncology, 2017, 9, 568-573.	0.7	3
48	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.8	6
49	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
50	Histologically benign, clinically aggressive: Progressive nonâ€optic pathway pilocytic astrocytomas in adults with NF1. American Journal of Medical Genetics, Part A, 2016, 170, 1455-1461.	1.2	16
51	Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Investigational New Drugs, 2016, 34, 149-158.	2.6	10
52	A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found <i>In Vivo</i> . Cancer Research, 2016, 76, 2465-2477.	0.9	453
53	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
54	MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell, 2016, 29, 49-60.	16.8	95

#	Article	IF	CITATIONS
55	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research, 2016, 22, 582-595.	7.0	88
56	Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 2015, 62, 1855-1858.	1.5	6
57	Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nature Cell Biology, 2015, 17, 170-182.	10.3	716
58	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015, 519, 366-369.	27.8	429
59	Consultative Issues in Surgical Neuropathology. American Journal of Clinical Pathology, 2015, 143, 807-811.	0.7	3
60	Supratentorial Tanycytic Ependymoma in an Adult Male: Case Report and Review of Literature. Case Reports in Oncology, 2015, 8, 159-163.	0.7	2
61	Prognostic marker analysis in pediatric intracranial ependymomas. Journal of Neuro-Oncology, 2015, 122, 255-261.	2.9	10
62	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. PLoS ONE, 2014, 9, e94281.	2.5	99
63	The Zinc Finger Transcription Factor ZFX Is Required for Maintaining the Tumorigenic Potential of Glioblastoma Stem Cells. Stem Cells, 2014, 32, 2033-2047.	3.2	47
64	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	21.4	148
65	High-Throughput Flow Cytometry Screening Reveals a Role for Junctional Adhesion Molecule A as a Cancer Stem Cell Maintenance Factor. Cell Reports, 2014, 6, 117-129.	6.4	76
66	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
67	Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth. Cell, 2013, 153, 139-152.	28.9	729
68	MET and ALK in glioblastoma multiforme (GBM): Comparison of IHC and FISH Journal of Clinical Oncology, 2012, 30, 2021-2021.	1.6	3
69	Glioblastoma Stem Cells: A Neuropathologist's View. Journal of Oncology, 2011, 2011, 1-8.	1.3	23
70	Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3. Cancer Cell, 2011, 19, 498-511.	16.8	233
71	Embryonal Central Nervous System Neoplasms Arising in Infants and Young Children: A Pediatric Brain Tumor Consortium Study. Archives of Pathology and Laboratory Medicine, 2011, 135, 984-993.	2.5	18
72	Reply to M.S. Lesniak. Journal of Clinical Oncology, 2011, 29, 3105-3106.	1.6	9

#	Article	IF	CITATIONS
73	Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells. Cancer Cell, 2009, 15, 501-513.	16.8	1,196
74	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology, 2009, 95, 393-400.	2.9	53
75	Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology, 2008, 10, 745-751.	1.2	61
76	c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells. PLoS ONE, 2008, 3, e3769.	2.5	352
77	Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology, 2007, 34, 405-413.	0.6	16
78	Second Messenger Systems in Human Gliomas. Archives of Pathology and Laboratory Medicine, 2007, 131, 1585-1590.	2.5	33
79	Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444, 756-760.	27.8	5,600
80	Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor. Cancer Research, 2006, 66, 7843-7848.	0.9	1,239
81	Errors in Surgical Neuropathology and the Influence of Cognitive Biases: The Psychology of Intelligence Analysis. Archives of Pathology and Laboratory Medicine, 2006, 130, 613-616.	2.5	12
82	Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer, 2005, 104, 1693-1699.	4.1	47
83	Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?. Cancer, 2003, 98, 1745-1748.	4.1	164
84	An anatomical investigation of the human cervical facet capsule, quantifying muscle insertion area. Journal of Anatomy, 2001, 198, 455-461.	1.5	54
85	Endodermal cyst of the oculomotor nerve. Neuroradiology, 2001, 43, 1063-1066.	2.2	36
86	CD34 and dural fibroblasts: the relationship to solitary fibrous tumor and meningioma. Acta Neuropathologica, 2001, 102, 349-354.	7.7	60
87	An anatomical investigation of the human cervical facet capsule, quantifying muscle insertion area. Journal of Anatomy, 2001, 198, 455-461.	1.5	20
88	HAM56-Immunoreactive Macrophages in Untreated Infiltrating Gliomas. Archives of Pathology and Laboratory Medicine, 2001, 125, 637-641.	2.5	19
89	Pathologic Quiz Case: Pituitary Mass in a 48-Year-Old Woman. Archives of Pathology and Laboratory Medicine, 2001, 125, 299-300.	2.5	4
90	Parasitic lesion of the insula suggesting cerebral sparganosis: case report. Neuroradiology, 2000, 42, 206-208.	2.2	24

#	Article	IF	CITATIONS
91	Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor. Journal of Histochemistry and Cytochemistry, 2000, 48, 1103-1110.	2.5	56
92	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology, 1999, 44, 233-241.	2.9	18
93	Topotecan treatment of adults with primary malignant glioma. Cancer, 1999, 85, 1160-1165.	4.1	65
94	Fine-needle aspiration cytology of ?ancient? schwannoma. , 1999, 20, 307-311.		68
95	Ependymomas: MIB-1 proliferation index and survival. Journal of Neuro-Oncology, 1998, 40, 51-57.	2.9	54
96	Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas., 1998, 30, 75-80.		14
97	False positive images in the follow-up of patients with brain tumors. , 1997, 28, 127-131.		8
98	Implantation metastasis of primary malignant rhabdoid tumor of the brain in an adult (one case) Tj ETQq0 0 0 rgl	BT /Overlo	ck <sub>4</sub> 10 Tf 50 4
99	Treatment of patients with pineoblastoma with high dose cyclophosphamide., 1996, 26, 387-392.		23
100	Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose Cyclophosphamide. Medical and Pediatric Oncology, 1996, 27, 32-39.	1.0	45
101	Microsatellite analysis of childhood brain tumors. , 1996, 15, 54-63.		40
102	Microsatellite analysis of childhood brain tumors. Genes Chromosomes and Cancer, 1996, 15, 54-63.	2.8	3
103	Tumor antigens in astrocytic gliomas. Glia, 1995, 15, 244-256.	4.9	110
104	Prognostic implications of chromosome 17p deletions in human medulloblastomas. Journal of Neuro-Oncology, 1995, 24, 39-45.	2.9	123
105	Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary report. Journal of Neuro-Oncology, 1995, 24, 109-122.	2.9	125
106	Clinicopathologic correlations in the oligodendroglioma. Cancer, 1987, 59, 1345-1352.	4.1	137
107	Adult respiratory distress syndrome after limited thoracic radiotherapy. Cancer, 1986, 57, 1941-1946.	4.1	33